ZTZoetis ZTS · NYSE
$79.71 +0.42% (+$0.33)
- Market cap
- $32.8B
- Enterprise value
- $40.6B
- P/E
- 12.5x
- Forward P/E
- 11.3x
- PEG
- 1.6x
- P/S
- 3.4x
- P/FCF
- 13.9x
- EV/EBITDA
- 10.5x
- ROIC
- 21.6%
- Gross margin
- 70.9%
- Net margin
- 27.5%
- Dividend yield
- 2.63%
- Payout ratio
- 33.0%
- Net debt/EBITDA
- 2.0x
- Beta
- 0.74
- Free float
- 99.8%
About the company
Zoetis Inc. (ZTS) is a global pharmaceutical company focused on animal health, headquartered in the USA. The company specializes in the development, manufacturing, and sale of medications and vaccines for animals. Zoetis provides a wide range of products for animal treatment and disease prevention in both domestic pets and livestock. Their portfolio includes medications for animals such as dogs, cats, cattle, pigs, poultry, and others. With its research, innovations, and global presence, Zoetis has gained a leading position in the field of animal health. The company focuses on improving the quality of life for animals and supports animal health worldwide. Zoetis Inc. (ZTS) shares can be an attractive investment opportunity for investors monitoring the animal health sector and valuing stability and long-term growth in this industry.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Kristin C. Peck
Employees
14,500
Headquarters
Parsippany
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number